相关实验视频
Updated: Jun 14, 2025

07:07
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
12.3K
在高级黑色素瘤中针对BRAF/MEK失败后,PARP抑制剂治疗的有效性
Jordan Phillipps1, George Nassief1, Renee Morecroft1
1Division of Medical Oncology, Department of Medicine, Washington University in Saint Louis, Saint Louis, MO 63130, USA.
NPJ precision oncology
|September 4, 2024
概括
多 (ADP-ribose) 聚合酶抑制剂 (PARPi) 与BRAF/MEK向治疗相结合,对抗标准治疗的晚期黑色素瘤患者显示有前途. 这种组合疗法为耐火性黑色素瘤病例提供了潜在的新方法.
科学领域:
- 在瘤学瘤学.
- 癌症治疗方法 癌症治疗方法
- 黑色素瘤研究 黑色素瘤研究
背景情况:
- 通过向治疗和免疫治疗,晚期黑色素瘤的生存率有所改善.
- 治疗耐药性和疾病进展仍然是晚期黑色素瘤的重大挑战.
- 多 (ADP-ribose) 聚合酶抑制剂 (PARPi) 在黑色素瘤治疗中显示出潜力.
研究的目的:
- 在晚期黑色素瘤中研究PARPi和BRAF/MEK抑制剂联合治疗的疗效.
- 探索耐火性晚期黑色素瘤患者的新型治疗策略.
主要方法:
- 关于三个患有BRAF V600突变黑色素瘤的高级患者的案例研究.
- 患者在标准BRAF/MEK向治疗中取得进展.
- 治疗涉及PARPi和BRAF/MEK抑制剂的组合.
主要成果:
- 这三名患者对组合疗法均表现出部分或几乎完全的反应.
- 组合方法在先进的黑色素瘤中表现出有效性,这些黑色素瘤在先前的治疗中耐药.
- 观察到PARPi和BRAF/MEK抑制剂之间的潜在协同作用.
结论:
- 组合PARPi和BRAF/MEK抑制剂疗法是针对针对性治疗耐药的晚期黑色素瘤的一个有希望的选择.
- 需要进一步的临床试验来验证这种协同效应在更大的患者队列中.
- 这种方法可以克服晚期黑色素瘤的耐治疗性.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K

